SI
IMMU

Stephens Inc’s Immunomedics Inc IMMU Stock Holding History

Stephens Inc’s Portfolio IMMU Stock Details IMMU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-13,000
Closed -$115K – 906
2017
Q2 		$115K Buy
+13,000
New +$91.3K ﹤0.01% 822
2016
Q4 		– Sell
-10,000
Closed -$33K – 830
2016
Q3 		$33K Hold
10,000
– – ﹤0.01% 756
2016
Q2 		$23K Buy
+10,000
New +$33.4K ﹤0.01% 752

Other funds holding IMMU

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Stephens Inc's IMMU Position: Q3 2017 in Review

Stephens Inc sold out of Immunomedics Inc (IMMU) in Q3 2017, closing a stake of 13,000 shares — an estimated $115K sold.

Stephens Inc first reported a position in IMMU in Q2 2016 and held it in 3 quarters. The position peaked at $115K in Q2 2017. 150 funds tracked by Wall St. Rank hold IMMU as of Q3 2017.

  • Stephens Inc reported no remaining Immunomedics Inc position as of Q3 2017 after selling out during the quarter.
  • Stephens Inc sold 13,000 Immunomedics Inc shares in Q3 2017, an estimated $115K.
  • Stephens Inc first reported a position in Immunomedics Inc in Q2 2016 and held it in 3 quarters.
  • Stephens Inc's Immunomedics Inc position peaked at $115K in Q2 2017.
  • 150 funds tracked by Wall St. Rank held Immunomedics Inc as of Q3 2017.

Based on Stephens Inc's 13F filing for Q3 2017, filed 8 Nov 2017.